Reduce the time and cost of securing clinical utility data to obtain coverage and reimbursement with private and public payers.
Gaining access to real-world clinical practice data can take months, if not years, and often millions of dollars to acquire. Whether you're evaluating new diagnostic tests, new therapeutic options, or new educational tools, QURE’s Simulated Clinical Trial Solutions provide evidence of clinical utility and accelerate market access at fraction of the time and cost. We can help ensure you generate robust clinical utility evidence to aid coverage and reimbursement efforts.
Key Benefits
QURE’s simulated clinical trials have been scientifically validated to elicit real-world clinical practice patterns from providers. This offers a novel, inexpensive way to reveal whether an intervention (therapeutic agent, diagnostic test, etc.) provides clinical utility. QURE can do this in a more cost-effective way than enrolling live patients in randomized controlled trials. Simulations meet all standards set by the Center for Medical Technology Policy on clinical utility.
QURE’s simulated clinical trials have been scientifically validated to elicit real-world clinical practice patterns from providers. This offers a novel, inexpensive way to reveal whether an intervention (therapeutic agent, diagnostic test, etc.) provides clinical utility. QURE can do this in a more cost-effective way than enrolling live patients in randomized controlled trials. Simulations meet all standards set by the Center for Medical Technology Policy on clinical utility.
Scientifically-validated virtual patient vignettes.
All participants care for the same virtual patients, eliminating patient variability while measuring physician behavior.
Results show that QURE's virtual patient cases document actual practice nearly as well as standardized patients (at a much lower cost) and better than chart abstraction.
"QURE data resulted in two high-quality, peer-reviewed publications demonstrating the clinical utility of our genetic test, that we’ve used successfully in coverage and reimbursement discussions with government and private payers.”
-Michael, CEO, Diagnostic Company